AbbVie (ABBV) Q3 2026 Earnings
Includes an unfavorable impact of $0.11 per share from acquired IPR&D and milestones expense ($216 million pre-tax, $205 million after-tax). GAAP diluted EPS of $2.37 additionally reflects intangible asset amortization ($1,669 million pre-tax), change in fair value of contingent consideration ($829 million pre-tax) and acquisition and integration costs ($408 million pre-tax, primarily Apogee Therapeutics).
How Did ABBV Stock React to Q3 2026 Earnings?
Did ABBV Beat Earnings? Q3 2026 Results
Yes. AbbVie reported Q3 2026 earnings of $3.82 a share on Oct 30, 2026, beating the $3.78 consensus estimate by 1.1%. Revenue was $17.4B against a $17.3B estimate.
AbbVie delivered a solid third quarter for fiscal 2026, posting adjusted diluted EPS of $3.82 against a consensus estimate of $3.78, a beat of roughly 1.09%, while revenue of $17.40 billion edged past the $17.35 billion estimate and grew 10.3% year over year. The headline driver was the company's post-Humira immunology franchise, where Skyrizi and Rinvoq surged 22.7% and 23.9% to $5.78 billion and $2.71 billion respectively, more than absorbing a 31.2% biosimilar-driven decline in Humira. Neuroscience also contributed meaningfully, rising 19.4% to $3.39 billion on broad gains across Vraylar, Qulipta, and Vyalev. Profitability improved sharply compared with the year-ago period, when a $2.70 billion acquired IPR&D charge had weighed heavily on results; this quarter's comparable figure was a much smaller $216 million pre-tax. With momentum building, AbbVie narrowed and raised its full-year 2026 adjusted diluted EPS guidance to $13.95 to $13.99, and the board lifted the quarterly dividend roughly 5.2% to $1.82, payable starting February 2027.
- Skyrizi revenue up 22.7% and Rinvoq up 23.9%
- Neuroscience portfolio up 19.4%, led by Vraylar, Qulipta, Ubrelvy and Vyalev
- Venclexta up 10.7% and Elahere up 31.0%
- Humira revenue down 31.2%
- Imbruvica revenue down 26.1%
- Juvederm revenue down 11.9%
- Lower acquired IPR&D and milestones expense ($216 million vs. $2.68 billion in the prior-year quarter)
- Adjusted operating margin of 48.7%
“AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio.”
AbbVie CEO, on the earnings call
What Is AbbVie's Outlook?
AbbVie raised its full-year 2026 adjusted diluted EPS guidance from $13.76–$13.96 to $13.95–$13.99. The range includes an unfavorable impact of $0.69 per share from acquired IPR&D and milestones expense incurred year-to-date through the third quarter. It excludes any acquired IPR&D and milestones that may be incurred beyond the third quarter, which cannot be reliably forecasted.
ABBV YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $17.4B | $15.8B | +10.3% |
| Operating Income | $6.3B | $1.9B | +229.2% |
| Net Income | $4.2B | $186.0M | +2,167.7% |
ABBV Revenue by Segment
ABBV Revenue by Geography
When Does AbbVie Report Next?
Figures from SEC filings and company reports. Not investment advice.